Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADT Inc (ADT) vs ARK Genomic Revolution ETF (ARKG) Price & Performance

ADT Inc
ARK Genomic Revolution ETF

Price performance

Price movement over the last 24 hours

Key statistics

ADT Inc vs ARK Genomic Revolution ETF — how do they compare? ADT Inc trades at $6.74 (market cap $5.07B), while ARK Genomic Revolution ETF trades at $41.16. The key difference: ADT Inc pays a 3.18% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, ADT Inc nearer its low. Which is the better fit depends on your goals.

ADTARKG
Market Cap
$5.07B
Sector
IndustrialsSector/Thematic
52-Week High
$8.85$43.57
52-Week Low
$6.30$23.09
Enterprise Value
$12.62B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADT Inc

ADT trades at $6.91, up 1.17% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with an 80.82% gross margin and 12.14% net margin, supported by positive news including recent industry awards and board participation in the Connectivity Standards Alliance. Cash flow from operations remains robust at $1.88 billion for 2025, though net cash flow was slightly negative.

Outlook is positive with analyst consensus leaning buy (47% buy ratings), but risks include high long-term debt of $7.51 billion and competitive pressures in home security. Revenue growth is stable, and valuation metrics like P/E of 8.88 suggest potential undervaluation, making it attractive for value-oriented investors mindful of leverage.

ARK Genomic Revolution ETF

ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.

The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.

Returns comparison

Trailing returns across standard periods

About ADT Inc

ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.

Read more on ADT

About ARK Genomic Revolution ETF

ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.

Read more on ARKG